Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

September 11, 2018

Primary Completion Date

September 15, 2020

Study Completion Date

October 15, 2020

Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
DRUG

Tropifexor (LJN452)

Comparison with monotherapy and different combination doses

DRUG

Cenicriviroc (CVC)

Comparison with monotherapy and different combination doses

Trial Locations (65)

2650

Novartis Investigative Site, Edegem

3000

Novartis Investigative Site, Leuven

20112

Novartis Investigative Site, Milan

23249

Novartis Investigative Site, Richmond

23298

Novartis Investigative Site, Richmond

27710

Novartis Investigative Site, Durham

28027

Novartis Investigative Site, Concord

28557

Novartis Investigative Site, Morehead City

30060

Novartis Investigative Site, Marietta

30309

Novartis Investigative Site, Atlanta

30312

Novartis Investigative Site, Atlanta

33604

Novartis Investigative Site, Pessac

34899

Novartis Investigative Site, Pendik / Istanbul

35100

Novartis Investigative Site, Izmir

37076

Novartis Investigative Site, Hermitage

37126

Novartis Investigative Site, Verona

37404

Novartis Investigative Site, Chattanooga

38138

Novartis Investigative Site, Germantown

39008

Novartis Investigative Site, Santander

41126

Novartis Investigative Site, Modena

46026

Novartis Investigative Site, Valencia

46237

Novartis Investigative Site, Indianapolis

55131

Novartis Investigative Site, Mainz

67098

Novartis Investigative Site, Strasbourg

70006

Novartis Investigative Site, Metairie

71103

Novartis Investigative Site, Shreveport

72117

Novartis Investigative Site, North Little Rock

75651

Novartis Investigative Site, Paris

78215

Novartis Investigative Site, San Antonio

84107

Novartis Investigative Site, Murray

85224

Novartis Investigative Site, Chandler

90048

Novartis Investigative Site, Los Angeles

90057

Novartis Investigative Site, Los Angeles

90127

Novartis Investigative Site, Palermo

91105

Novartis Investigative Site, Pasadena

92118

Novartis Investigative Site, Coronado

92377

Novartis Investigative Site, Rialto

97080

Novartis Investigative Site, Würzburg

98104

Novartis Investigative Site, Seattle

101990

Novartis Investigative Site, Moscow

109544

Novartis Investigative Site, Moscow

110070

Novartis Investigative Site, New Delhi

117549

Novartis Investigative Site, Singapore

169608

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

60637-1470

Novartis Investigative Site, Chicago

02905

Novartis Investigative Site, Providence

75208-2312

Novartis Investigative Site, Dallas

C1181ACH

Novartis Investigative Site, CABA

C1280AEB

Novartis Investigative Site, Caba

C1073ABA

Novartis Investigative Site, San Juan Bautista

V6Z 2K5

Novartis Investigative Site, Vancouver

M5G 2C4

Novartis Investigative Site, Toronto

M6H 3MI

Novartis Investigative Site, Toronto

G7H 7K9

Novartis Investigative Site, Chicoutimi

H4A 3J1

Novartis Investigative Site, Montreal

128 08

Novartis Investigative Site, Prague

Unknown

Novartis Investigative Site, Shebeen El-Kom

00168

Novartis Investigative Site, Roma

LV-1006

Novartis Investigative Site, Riga

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

NE7 7DN

Novartis Investigative Site, High Heaton

AB25 2ZN

Novartis Investigative Site, Aberdeen

TQ2 7AA

Novartis Investigative Site, Torquay

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY